Schonfeld Strategic Advisors LLC
Position in ANIK — Anika Therapeutics, Inc.
CIK 1665241
NEW YORK, NY
Position in ANIK
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$159,804
-$190,769 QoQ
Shares Held
11,021
+11.3% QoQ
Ownership
0.083%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2020
3 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ANIK Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Mar 31, 2026Schonfeld Strategic Advisors LLC holds $50,240,980 across 18 Drug Manufacturers - Specialty & Generic names. ANIK ranks #16 (0.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ANIP |
Ani Pharmaceuticals Inc
|
185,629 | $14,274,870 | |
| 2 | BCRX |
Biocryst Pharmaceuticals Inc
|
1,337,693 | $12,734,837 | |
| 3 | NBIX |
Neurocrine Biosciences Inc
|
56,615 | $7,458,460 | |
| 4 | UTHR |
UNITED THERAPEUTICS Corp
|
4,290 | $2,543,884 | |
| 5 | SUPN |
Supernus Pharmaceuticals, Inc.
|
48,765 | $2,520,662 | |
| 6 | KNSA |
Kiniksa Pharmaceuticals International, plc
|
43,599 | $2,099,291 | |
| 7 | ZTS |
Zoetis Inc.
|
16,271 | $1,923,394 | |
| 8 | XERS |
Xeris Biopharma Holdings, Inc.
|
296,431 | $1,719,299 |
All Filings in ANIK
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $159,804 | 11,021 | Shares | Sole | 2026-05-15 | |
| 2020-09-30 | $350,573 | 9,906 | Shares | Sole | 2020-11-19 | |
| 2020-03-31 | $301,357 | 10,424 | Shares | Sole | 2020-05-15 | |
| No filing history on record for this holder in this stock. | ||||||